Greece · Delayed Price · Currency is EUR Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 139.17 million. The enterprise value is 166.81 million.
| Market Cap | 139.17M |
| Enterprise Value | 166.81M |
Important Dates
The last earnings date was Monday, November 17, 2025.
| Earnings Date | Nov 17, 2025 |
| Ex-Dividend Date | Jul 17, 2025 |
Share Statistics
Lavipharm has 168.69 million shares outstanding.
| Current Share Class | 168.69M |
| Shares Outstanding | 168.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.21% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 3.39% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 67.53.
| PE Ratio | 67.53 |
| Forward PE | n/a |
| PS Ratio | 2.53 |
| PB Ratio | 2.48 |
| P/TBV Ratio | 11.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 50.98 |
| EV / Sales | 3.03 |
| EV / EBITDA | 16.64 |
| EV / EBIT | 33.22 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 3.37 |
| Debt / FCF | n/a |
| Interest Coverage | 2.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 195,411 |
| Profits Per Employee | 11,603 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lavipharm has paid 1.32 million in taxes.
| Income Tax | 1.32M |
| Effective Tax Rate | 39.01% |
Stock Price Statistics
The stock price has increased by +16.20% in the last 52 weeks. The beta is 0.63, so Lavipharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +16.20% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 0.81 |
| Relative Strength Index (RSI) | 52.21 |
| Average Volume (20 Days) | 204,566 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 55.11 million and earned 3.27 million in profits. Earnings per share was 0.02.
| Revenue | 55.11M |
| Gross Profit | 24.37M |
| Operating Income | 5.02M |
| Pretax Income | 3.38M |
| Net Income | 3.27M |
| EBITDA | 9.28M |
| EBIT | 5.02M |
| Earnings Per Share (EPS) | 0.02 |
Balance Sheet
The company has 6.17 million in cash and 33.81 million in debt, giving a net cash position of -27.64 million or -0.16 per share.
| Cash & Cash Equivalents | 6.17M |
| Total Debt | 33.81M |
| Net Cash | -27.64M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 56.08M |
| Book Value Per Share | 0.33 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 44.22%, with operating and profit margins of 9.11% and 5.94%.
| Gross Margin | 44.22% |
| Operating Margin | 9.11% |
| Pretax Margin | 6.14% |
| Profit Margin | 5.94% |
| EBITDA Margin | 16.84% |
| EBIT Margin | 9.11% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 2.44%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 2.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 2.44% |
| Earnings Yield | 2.35% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |